Methylprednisolone
- PDF / 170,279 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 8 Downloads / 179 Views
1 S
Steroid diabetes: case report An approximately 43-year-old man developed steroid diabetes during treatment with methylprednisolone for malignant thymoma. In May 2007 (at the age of 39 years), the man initially presented to hospital with symptoms of cough and runny nose. Following examinations, he was diagnosed with malignant thymoma clinical stage III (type B2 as per WHO classification). Subsequent treatments included two cycles of chemotherapy with cisplatin and etoposide, followed by ADOC regimen containing doxorubicin [adriamycin], cisplatin, vincristine and cyclophosphamide for six cycles. Thereafter (in September 2007), due to only partial regression, he underwent surgical debulking of the tumour, which was unsuccessful. After that, he received concurrent chemoradiotherapy till March 2008 with cisplatin. In April 2009, a new tumour lesion was noted, and he received five cycles of the ADOC regimen leading to disease stabilisation. In January 2010, disease progression with metastases was noted, and he received four additional cycles of the ADOC regimen with moderate effect. Disease progression was again noted in September 2010, and he received six cycles of cisplatin and etoposide leading to disease stabilisation. In May 2011, disease progression was again noted. Hence, he received a combination of somatostatin analogue octreotide [Sandostatin LAR] and oral methylprednisolone [Medrol] 32 mg/day. In July 2011, examinations showed marked regression and stabilisation of the primary tumour. However, he developed steroid therapy related diabetes [duration of treatment to reaction onset not stated ]. The man’s methylprednisolone therapy dose was tapered to 24mg, which was well tolerated [outcome not stated]. However, in January 2012, further disease progression was noted, and the therapy was stopped. Thereafter, he received six cycles of docetaxel, followed by gemcitabine. In April 2014, after 3 cycles of gemcitabine progression was noted. After that, he was placed on basic supportive care due to lack of treatment options. He died on February 2015 [immediate cause of death not stated]. Sorejs O, et al. Octreotide in the treatment of malignant thymoma - Case report. Reports of Practical Oncology and Radiotherapy 25: 882-885, No. 6, Dec 2020. Available 803506652 from: URL: http://doi.org/10.1016/j.rpor.2020.08.012
0114-9954/20/1825-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 10 Oct 2020 No. 1825
Data Loading...
